Changing treatment paradigms for the management of inflammatory bowel disease
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Inf lammatory bowel disease (IBD) is a chronic and progressive inf lammatory condition of the gastrointestinal tract causing bowel damage, hospitalizations, surgeries, and disability. Although there has been much progress in the management of IBD with established and evolving therapies, most current approaches have failed to change the natural course. Therefore, the treatment approach and follow-up of patients with IBD have undergone a significant change. Usage of immunosuppressants and/or biologics early during the course of the disease, known as top-down or accelerated step-up approach, was shown to be superior to conventional management in patients who had been recently diagnosed with IBD. This approach can be applied to selected groups based on prognostic factors to control disease activity and prevent progressive disease. Therapeutic targets have been shifted from clinical remission mainly based on symptoms to objective parameters such as endoscopic healing due to the discrepancies observed between symptoms, objectively evaluated inf lammatory activity, and intestinal damage. The concept of treat-to-target in IBD has been supported by population-based cohort studies, post hoc analysis of clinical trials, and meta-analysis, but more evidence is needed to support this concept to be applied to the clinical practice. In addition, individualized approach with tight monitoring of non-invasive biomarker such as C-reactive protein and fecal calprotectin and drug concentration has shown to improve clinical and endoscopic outcomes. An appropriate de-escalation strategy is considered based on patient demographics, disease features, current disease status, and patients’ preferences.
Abstract
Inf lammatory bowel disease (IBD) is a chronic and progressive inf lammatory condition of the gastrointestinal tract causing bowel damage, hospitalizations, surgeries, and disability. Although there has been much progress in the management of IBD with established and evolving therapies, most current approaches have failed to change the natural course. Therefore, the treatment approach and follow-up of patients with IBD have undergone a significant change. Usage of immunosuppressants and/or biologics early during the course of the disease, known as top-down or accelerated step-up approach, was shown to be superior to conventional management in patients who had been recently diagnosed with IBD. This approach can be applied to selected groups based on prognostic factors to control disease activity and prevent progressive disease. Therapeutic targets have been shifted from clinical remission mainly based on symptoms to objective parameters such as endoscopic healing due to the discrepancies observed between symptoms, objectively evaluated inf lammatory activity, and intestinal damage. The concept of treat-to-target in IBD has been supported by population-based cohort studies, post hoc analysis of clinical trials, and meta-analysis, but more evidence is needed to support this concept to be applied to the clinical practice. In addition, individualized approach with tight monitoring of non-invasive biomarker such as C-reactive protein and fecal calprotectin and drug concentration has shown to improve clinical and endoscopic outcomes. An appropriate de-escalation strategy is considered based on patient demographics, disease features, current disease status, and patients’ preferences.
참고문헌 (45)
- Laura E. Raffals, "Navigating the Microbial Basis of Inflammatory Bowel Diseases: Seeing the Light at the End of the Tunnel", Gut and Liver, 10(4), pp.502~508 (2016), 거트앤리버 소화기연관학회협의회
- Kaplan GG, "Understanding and preventing the global increase of inflammatory bowel disease", Gastroenterology, 152, pp.313~321 (2017)[DOI]
- Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
- Peyrin-Biroulet L, "Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts", Inflamm Bowel Dis, 17, pp.471~478 (2011)[DOI]
- Torres J, "Ulcerative colitis as a progressive disease: the forgotten evidence", Inflamm Bowel Dis, 18, pp.1356~1363 (2012)[DOI]
- Solberg IC, "Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study)", Inflamm Bowel Dis, 20, pp.60~68 (2014)[DOI]
- 윤진영, "Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life", Gut and Liver, 11(3), pp.370~376 (2017), 거트앤리버 소화기연관학회협의회
- 송혜경, "Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn’s and Colitis (AOCC) meeting in Seoul", Intestinal research, 14(3), pp.240~247 (2016), 대한장연구학회
- Colombel JF, "Management strategies to improve outcomes of patients with inflammatory bowel diseases", Gastroenterology, 152, pp.351~361 (2017)[DOI]
- D'Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial", Lancet, 371, pp.660~667 (2008)[DOI]
- Colombel JF, "Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis", Gastroenterology, 141, pp.1194~1201 (2011)[DOI]
- Colombel JF, "Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease. A SONIC post hoc analysis", Aliment Pharmacol Ther, 41, pp.734~746 (2015)[DOI]
- Park SH, "Long-term prognosis of Crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea", Inflamm Bowel Dis, 20, pp.488~494 (2014)[DOI]
- Lee HS, "Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea", J Crohns Colitis, 9, pp.147~155 (2015)[DOI]
- Solberg IC, "Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study", Clin Gastroenterol Hepatol, 5, pp.1430~1438 (2007)[DOI]
- Khanna R, "Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial", Lancet, 386, pp.1825~1834 (2015)[DOI]
- Oh EH, "Early anti-TNF", immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors, 2017, pp.12, e0177479~
- 김지연, "Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study", The Korean Journal of Internal Medicine, 32(1), pp.69~83 (2017), 대한내과학회[DOI]
- Park Y, "Development of a novel predictive model for the clinical course of Crohn's disease: results from the CONNECT study", Inflamm Bowel Dis, 23, pp.1071~1079 (2017)[DOI]
- Jones J, "Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease", Clin Gastroenterol Hepatol, 6, pp.1218~1224 (2008)[DOI]
- Froslie KF, "Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort", Gastroenterology, 133, pp.412~422 (2007)[DOI]
- Shah SC, "Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 14, pp.1245~1255 (2016)[DOI]
- Colombel JF, "Adalimumab induces deep remission in patients with Crohn's disease", Clin Gastroenterol Hepatol, 12, pp.414~422 (2014)[DOI]
- Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-totarget", Am J Gastroenterol, 110, pp.1324~1338 (2015)[DOI]
- 김은수, "Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization for Crohn’s and Colitis (AOCC) meeting in Seoul", Intestinal research, 14(3), pp.224~230 (2016), 대한장연구학회
- Bryant RV, "Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up", Gut, 65, pp.408~414 (2016)[DOI]
- Shu-Chen Wei, "Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease", Intestinal research, 15(3), pp.285~310 (2017), 대한장연구학회
- Panes J, "Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases", Gastroenterology, 152, pp.362~373 (2017)[DOI]
- Colombel JF, "Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial", Lancet (2017)
- Qiao Yu, "Surgical management of inflammatory bowel disease in China: a systematic review of two decades", Intestinal research, 14(4), pp.322~332 (2016), 대한장연구학회
- 박재준, "Second Korean guidelines for the management of Crohn’s disease", Intestinal research, 15(1), pp.38~67 (2017), 대한장연구학회
- De Cruz P, "Crohn's disease management after intestinal resection: a randomised trial", Lancet, 385, pp.1406~1417 (2015)[DOI]
- Wright EK, "Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery", Gastroenterology, 148, pp.938~947 (2015)[DOI]
- 은창수, "Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?", Gut and Liver, 11(1), pp.3~4 (2017), 거트앤리버 소화기연관학회협의회
- Mitrev N, "Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases", Aliment Pharmacol Ther, 46, pp.1037~1053 (2017)[DOI]
- Papamichael K, "Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab", Clin Gastroenterol Hepatol, 15, pp.1580~1588 (2017)[DOI]
- Roblin X, "Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases", Am J Gastroenterol, 109, pp.1250~1256 (2014)[DOI]
- Kai-Chun Wu, "Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn’s disease", Intestinal research, 14(2), pp.152~163 (2016), 대한장연구학회
- Williet N, "Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months", Clin Gastroenterol Hepatol, 15, pp.1750~1757 (2017)[DOI]
- Kaplan GG, "The global burden of IBD: from 2015 to 2025", Nat Rev Gastroenterol Hepatol, 12, pp.720~727 (2015)[DOI]
- 이장욱, "Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease", Intestinal research, 14(2), pp.146~151 (2016), 대한장연구학회
- 이강문, "Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)", Intestinal research, 13(3), pp.193~207 (2015), 대한장연구학회
- Torres J, "Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease", Gastroenterology, 149, pp.1716~1730 (2015)[DOI]
- Louis E, "Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped", Gastroenterology, 142, pp.63~70 (2012)[DOI]
- Pariente B, "Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases", Aliment Pharmacol Ther, 40, pp.338~353 (2014)[DOI]